Valuation: Celsion Corporation

Market Cap 66.78L 59.5L 55.09L 49.86L 93.93L 63Cr 95.04L 6.61Cr 2.59Cr 33Cr 2.5Cr 2.45Cr 105.55Cr P/E 2026 *
-0.5x
P/E 2027 * -0.64x
Enterprise Value 66.78L 59.5L 55.09L 49.86L 93.93L 63Cr 95.04L 6.61Cr 2.59Cr 33Cr 2.5Cr 2.45Cr 105.55Cr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.73%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Celsion Corporation

Manager TitleAgeSince
Chief Executive Officer 56 13/05/2024
Director of Finance/CFO 53 01/07/2026
Chief Tech/Sci/R&D Officer 73 18/02/2025
Director TitleAgeSince
Chairman 75 07/10/2014
Director/Board Member 75 08/07/2011
Director/Board Member 76 15/12/2015
Change 5-day change 1-year change 3-year change Capi.($)
-0.21%-4.43%+44.40%+74.13% 6.63TCr
+0.82%+5.41%+8.05%+73.53% 5.48TCr
-0.22%+6.53%+11.68%+87.32% 5.29TCr
+3.28%+5.58%+26.51%+50.05% 4.41TCr
+0.51%+9.95%+22.40%+133.92% 4.37TCr
-1.15%+0.39%+263.21%+594.60% 4.21TCr
+0.10%+9.90%+16.11%+59.33% 3.4TCr
-5.59%-3.99%+30.37%+1.19% 2.62TCr
+0.69%+5.60%+36.60%+26.94% 2.34TCr
Average -0.18%+4.74%+51.04%+122.33% 4.31TCr
Weighted average by Cap. +0.04%+4.54%+50.16%+127.37%

Financials

2026 *2027 *
Net sales - -
Net income -1.45Cr -1.29Cr -1.19Cr -1.08Cr -2.04Cr -136.52Cr -2.06Cr -14Cr -5.62Cr -72Cr -5.43Cr -5.31Cr -228.67Cr -1.86Cr -1.65Cr -1.53Cr -1.39Cr -2.61Cr -175.07Cr -2.64Cr -18Cr -7.2Cr -92Cr -6.96Cr -6.81Cr -293.24Cr
Net Debt - -
Logo Celsion Corporation
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Celsion Corporation